Laurus Labs Quarterly Results for Trading Insights
In Mar 2026, Laurus Labs (LAURUSLABS) reported revenue ₹1,823 Cr and net profit ₹282 Cr — revenue +2.5% YoY. Also explore LAURUSLABS share price data to track price trends across different timeframes.
LAURUSLABS Quarterly Results — Revenue, Profit & EPS Highlights
Laurus Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit LAURUSLABS share price screener.
- Revenue of ₹1,823 Cr in Mar 2026 (+8.5% vs Sept 2025, +2.5% vs Mar 2025)
- Net Profit of ₹282 Cr in Mar 2026 (+44.6% vs Sept 2025, +21.0% vs Mar 2025)
- EBITDA of ₹524 Cr in Mar 2026 (+21.9% vs Sept 2025)
- Operating Margin of 28.0% in Mar 2026 (+4.0pp vs Sept 2025)
- Earnings Per Share of ₹5.17 in Mar 2026 (+43.2% vs Sept 2025)
Laurus Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
LAURUSLABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,823 | 1,680 | 1,779 | 1,580 | 1,784 | 8.5% | 2.5% |
| Net Profit (₹ Cr) | 282 | 195 | 233 | 162 | 252 | - | - |
| EBITDA (₹ Cr) | 524 | 430 | 479 | 393 | 486 | - | - |
| EPS (₹) | 5.17 | 3.61 | 4.34 | 3.02 | 4.67 | - | - |
| Operating Margin (%) | 28.0% | 24.0% | 24.0% | 24.0% | 27.0% | - | - |
LAURUSLABS Share Price Trend — 1-Year Movement Across Quarterly Results
Laurus Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with LAURUSLABS fair price to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
LAURUSLABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Laurus Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores